Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | AXL | P30530 | 5/20 | 0.40 |
| ▸ | MET | P08581 | 5/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656353 | 0.91 | ESR1 (0.42) | KDRPDGFRAMAPTEGLN1LCK | |
| SCHEMBL1658690 | 0.90 | EGLN1 (0.47) | EGLN1 | |
| SCHEMBL1656615 | 0.84 | MTNR1B (0.45) | PDGFRAMAPT | |
| SCHEMBL28055652 | 0.84 | EGLN1 (0.44) | MAOASCN9AMAPTEGLN1ABL1 | |
| SCHEMBL1656086 | 0.82 | HTT (0.41) | MAPTEGLN1LCK | |
| SCHEMBL1656052 | 0.82 | MAOA (0.40) | MAOAKDRPDGFRAFPR2SCN9A | |
| SCHEMBL3782810 | 0.81 | EGLN1 (0.61) | EGLN1 | |
| SCHEMBL1655799 | 0.78 | EGLN1 (0.45) | MAOAKDRPDGFRAAXLMET | |
| SCHEMBL31225053 | 0.76 | NR4A2 (0.42) | EGLN1LCK | |
| SCHEMBL1656383 | 0.75 | EGLN1 (0.45) | KDRPDGFRAAXLMETSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8759373-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2476669-A1 | Cyanoisoquinoline compounds and methods of use thereof | Fibrogen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2044028-B1 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | FIBROGEN, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7928120-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | MAOA 924/4885KDR 1047/4885PDGFRA 1296/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | MAOA 2421/4885KDR 444/4885PDGFRA 481/4885 |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | MAOA 2421/4885KDR 444/4885PDGFRA 481/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | MAOA 2421/4885KDR 444/4885PDGFRA 481/4885 |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | HIF1AN, HIF1A, EGLN3 | MAOA 2421/4885KDR 444/4885PDGFRA 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.